Shed it, and help—LAG3 cleavage drives conventional CD4 + T cells to overcome resistance to PD-1 immunotherapy
- 3 July 2020
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (49)
- https://doi.org/10.1126/sciimmunol.abc8644
Abstract
LAG3 cleavage from conventional CD4+ T cells, but not CD8+ T cells, is required for effective PD-1 blockade.Keywords
This publication has 10 references indexed in Scilit:
- Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 sheddingScience Immunology, 2020
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3Cell, 2018
- PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 TherapyCancer Immunology Research, 2018
- LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCIINature Immunology, 2018
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature, 2017
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependentScience, 2017
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- Metalloproteases regulate T-cell proliferation and effector function via LAG-3The EMBO Journal, 2007